InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar diansacc (< 20) Submitted: 12/27/2010 5:14:57 PM : Underperform Start Price: $38.01 ITMN Score: +76.70

itmn

Featured Broker Partners


Advertisement